Genvoya

DRUG5 trials

Sponsors

University of California, San Diego, Emory University, Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux, Saskatchewan Health Authority - Regina Area

Conditions

Bone Diseases, MetabolicBuprenorphine DependenceCo-infectionHCV CoinfectionHIVHIV InfectionsHIV RiskHIV-1-infection

Phase 1

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

CompletedNCT02985996

Emory UniversityHIV Infections

Start: 2017-02-06End: 2017-11-29Updated: 2019-09-17

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

CompletedNCT03976752

Emory UniversityHIV/AIDS

Start: 2019-03-13End: 2019-09-20Updated: 2021-08-13

Phase 3

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

CompletedNCT02998320

Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents InfectieuxHIV Risk

Start: 2017-03-10End: 2018-09-30Updated: 2019-02-15

Phase 4

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Saskatchewan Health Authority - Regina AreaBone Diseases, Metabolic, Buprenorphine Dependence, Co-infection +6

Start: 2018-02-01End: 2021-06-22Target: 25Updated: 2019-12-24

Unknown Phase

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

CompletedNCT02251236

University of California, San DiegoHIV

Start: 2016-01-31End: 2017-01-18Updated: 2019-10-31

Related Papers

Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid

Clinical Infectious Diseases2019-09-1811 citations

Elvitegravir–Cobicistat–Emtricitabine–Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis

Clinical Infectious Diseases2019-06-2712 citations